Anchiano Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies to treat cancer-related diseases. Its most advanced product candidate, BC-819, is under development as a treatment for non-muscle-invasive bladder cancer. Anchiano also develops a second-generation drug, BC-821, for the systemic treatment of advanced malignant neoplasms. Preclinical studies of BC-821 have showed significant efficacy in different cancer animal models, such as metastatic lung cancer and metastatic liver cancer. AnchianoTherapeutics is a direct subsidiary of Clal Biotechnology Industries Ltd.
Cumulative Funding Raised Over Time ($)
Employees Over Time
Anchiano Therapeutics Climate Tech relevance
null
Latest News
No Data, yet.
Sorry, no content found under this section.
Mar 16, 2021
www.prnewswire.com
Chemomab Completes Merger with Anchiano Therapeutics